Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pierre Boutouyrie1

  • 1Service de pharmacologie, INSERM U970, hôpital européen Georges-Pompidou, université de Paris, Assitance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France.

Therapie
|March 5, 2020
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tonometer- and ultrasound-based pulse wave analysis - a comparative study.

Computer methods and programs in biomedicine·2026
Same author

Sex-Specific trajectories of arterial stiffness: a large-scale description of 38 million real-world pulse wave velocity measurements.

Frontiers in cardiovascular medicine·2026
Same author

Effects of microgravity on human physiology.

Progress in biophysics and molecular biology·2026
Same author

Radiomics-Based Classification of Pathological Patterns in Common Carotid Artery Wall.

Ultrasound in medicine & biology·2026
Same author

A constitutive modelling framework for applications to in vivo longitudinal data: Evaluation in a 60-day head-down bed rest study on arterial function.

The Journal of physiology·2026
Same author

Preventing the stiffening aorta: a call for sex-specific hypertension management in midlife.

European journal of preventive cardiology·2026
Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026
Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026
Same journal

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge.

Therapie·2026
Same journal

Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.

Therapie·2026
Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026
See all related articles

Celiprolol, a beta-blocker, significantly reduced major adverse events in patients with vascular Ehlers-Danlos syndrome by threefold. This finding offers a promising new treatment for this rare genetic connective tissue disorder.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Medicine
  • Rare Diseases

Background:

  • Vascular Ehlers-Danlos syndrome (vEDS) is a severe genetic connective tissue disorder.
  • Caused by mutations in the COL3A1 gene, vEDS presents with arterial dissections, organ ruptures, and tissue fragility.
  • Currently, no specific treatments are available for vEDS.

Purpose of the Study:

  • To evaluate the efficacy of celiprolol as a treatment for vascular Ehlers-Danlos syndrome.
  • To assess the impact of celiprolol on major adverse events in vEDS patients.

Main Methods:

  • A randomized, controlled trial was conducted to test celiprolol.
  • Celiprolol, a beta-blocker with specific antagonist properties, was administered to patients.
  • Patient outcomes were compared between the treatment and control groups.
Keywords:
CeliprololRandomized controlled trialVascular Ehlers-Danlos syndrome

Related Experiment Videos

Main Results:

  • Celiprolol administration resulted in a threefold decrease in major disease-related events.
  • The observed benefit was consistent in patients with molecularly confirmed vEDS.
  • Real-world data from a French cohort showed similar positive outcomes with routine celiprolol administration.

Conclusions:

  • Celiprolol demonstrates significant therapeutic potential for vascular Ehlers-Danlos syndrome.
  • This beta-blocker represents the first effective treatment option for vEDS.
  • Further investigation and regulatory review (e.g., FDA New Drug Application) are underway for celiprolol availability.